Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Further prospective trials are required to define its clinical role
The Phase 2 obesity trial (Jastreboff et al., NEJM 2023) reported substantial reductions in body weight, with some participants achieving losses exceeding 20% of their baseline body weight at the highest doses studied
All analyses were performed using reproducible data-processing scripts, with drug-specific analyses conducted independently
doi: 10.3390/ijms23116093 96 LanTWangWZengXXTongYHMaoZJWangSW
Benefits include: Average weight loss of up to 15 to 25% in clinical studies Improved portion control and satiety Support for balancing blood sugar and metabolic health GLP-1/GIP Dual Agonists These advanced options activate both GLP-1 and GIP (gastric inhibitory polypeptide) receptors for enhanced appetite control, glucose balance, and fat metabolism
US$ 29.58
US$ 20.83
US$ 21.21
US$ 23.32
